Your AI-Trained Oncology Knowledge Connection!
Due to advances in chemotherapy, biologic therapy, and the development of liver-oriented treatment options, the survival of patients with metastatic cancer has more than doubled, and increasing numbers of patients have been cured, even among those with advanced disease.
This article will review the current practice of hepatic resection for colorectal liver metastases, including the possibility of combined resection of hepatic metastases at the time of resection of the primary cancer.
People who underwent genetic and environmental risk assessment evaluating their colorectal cancer risk were no more likely to undergo screening for the disease.
Only 14% of newly diagnosed lung or colorectal cancer patients reported discussing clinical trial participation with their physician, and fewer participated.
Adopting a combination of five healthy behaviors is linked to a reduction in the risk of developing colorectal cancer, according to the results of a study.
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.
The management of colorectal cancer is a complex endeavor that requires treatment individualization founded on molecular characterization of the tumor, an in-depth understanding of the patient, and an appreciation of the interaction between the two.
A 35-year study of males in Sweden found a link between obesity and inflammation during adolescence and a risk for colorectal cancer in adulthood.
Two French studies have shown that screening for colorectal cancer with fecal occult blood tests can be very effective, according to results presented at the ESMO 2014 Congress.
Adding cetuximab (Erbitux) to the standard first-line FOLFIRI chemotherapy regimen results in longer overall survival in metastatic colorectal cancer patients.
A systematic, best-practice approach to colorectal surgery can decrease the risk of surgical site infections, according to a new study.
This article discusses features that predict local recurrence and distant metastasis in rectal cancer, and how to use MRI to guide treatment decisions.
There are a number of clinicopathologic variables that predict outcome in rectal cancer. In the era of postoperative chemoradiation treatment, these were more easily identified and were used to help select patients for adjuvant therapy.
The authors propose that current policies regarding the use of chemoradiotherapy or short-course preoperative radiotherapy have resulted in an approach to rectal cancer management that often represents overtreatment, with significant loss of quality of life for patients.
Yesterday, the US Food and Drug Administration (FDA) approved the first DNA-based stool sample screening test for colorectal cancer.
A comprehensive analysis of studies and trials suggests the cancer prevention benefits of a daily aspirin for at least 5 years outweigh the potential harms.
Rectal cancer management is becoming increasingly complex. There is increasing recognition of the potential to avoid routine chemoradiotherapy, as excellent results can be achieved with a more selective approach.
Although the current standard treatment for patients with locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision, concerns have been raised over the functional sequelae and possible overtreatment of rectal cancer patients.
In this article, we review risks and benefits of the standard treatment approach for rectal cancer and compare standard treatment with alternative methods aimed at rectal preservation.
Colorectal cancer patients with higher levels of plasma vitamin D have better survival outcomes, according to a new prospective study.
Age is a prognostic factor for both overall survival and progression-free survival among patients diagnosed with metastatic colorectal cancer, according to the results of a study.
Consuming more than two servings of fish each week can reduce a person’s risk for recurrence of colorectal cancer, according to the results of a cross-sectional multinational study.
The landscape of cancer therapy is shifting from traditional cytotoxic chemotherapy towards targeted therapy with agents like tyrosine kinase inhibitors and monoclonal antibodies. However, these newer agents remain costly, and traditional chemotherapy remains the backbone for treating most malignancies.
Methods of screening for colorectal cancer are estimated to have prevented between a quarter of a million to a half a million colorectal cancers, according to a recently published study.
